Numiera repositions Etomoxir for glioblastoma

Numiera Therapeutics presented preclinical and clinical safety data on Etomoxir at the EACR Meeting on Cancer Metabolism in Bilbao this week, arguing the CPT1 inhibitor could be repurposed for glioblastoma. The company is leaning on a growing body of academic research and prior heart-failure trial data as it looks to advance the orphan-designated asset in a hard-to-treat brain cancer.

Why it matters: - Glioblastoma is the most common primary malignant brain tumor in adults. - The disease has a poor prognosis and few treatment options. - Standard-of-care temozolomide provides limited benefit and brings notable side effects. - A repurposed therapy could offer a faster path than developing a drug from scratch.

What happened: - Numiera Therapeutics presented data this week at the European Association for Cancer Research Meeting on Cancer Metabolism in Bilbao, Spain. - The company used the meeting to support repositioning Etomoxir, a first-in-class CPT1 inhibitor, for glioblastoma. - Numiera describes Etomoxir as its orphan-designated lead asset. - The presentation covered both clinical safety data and preclinical efficacy data.

The details: - Five independent academic laboratories have shown that glioblastoma cells rely primarily on fatty acid oxidation for energy. - Those studies also found that Etomoxir significantly slowed glioblastoma tumor growth in mouse models as a single agent. - Etomoxir was originally developed for diabetes and congestive heart disease, with the goal of improving glucose utilization and cardiometabolic function. - In the ERGO Phase I/II trial in patients with congestive heart failure, fewer deaths occurred in the 40 mg Etomoxir group and the 80 mg group than in the placebo or untreated group, although the finding was not significant. - Elevated liver transaminase levels appeared in 4 patients across the treated cohort and reversed after drug withdrawal. - Temozolomide is associated with elevated liver transaminase levels in more than 12% of patients, along with thrombocytopenia, bone marrow depletion and hair loss. - Numiera CEO Izi Stoll said the company’s work on cancer-cell metabolism led to a new targeted treatment concept. - Stoll said the company believes aggressive cancer cells use glucose to make DNA and RNA while fatty acids serve as the primary fuel for energy production. - Stoll said blocking CPT1 prevents cancer cells from making enough energy to sustain malignant growth. - Director of Commercialization Strategy Anjali Hansen said the Phase I clinical data and scientific consensus around the target guided the decision to reposition Etomoxir for glioblastoma.

Between the lines: - Numiera is trying to turn a cardiometabolic drug into an oncology asset by linking tumor biology to energy metabolism. - The strategy depends on two pillars: published preclinical evidence and a prior human safety dataset from a different disease area. - The company is also framing the drug against temozolomide, the current standard, to emphasize unmet need and tolerability. - The move reflects a broader biotech playbook: repurpose known compounds where the underlying mechanism is already supported by external research.

What's next: - Numiera says it looks forward to evaluating Etomoxir as a therapeutic option for glioblastoma patients. - The company’s forward-looking statements indicate future work may include clinical and non-clinical trial readouts, enrollment plans and further development of its candidate products. - Any next-stage progress will likely depend on whether the preclinical signal translates into human efficacy and acceptable safety in oncology.